John M Lund Photography Inc/DigitalVision via Getty Images Investment Overview - Cabaletta's Miraculous Recovery On Potential Best-In-Class Autoimmune Cell Therapy I last covered Cabaletta Bio, Inc. (NASDAQ:CABA) in a note for Seeking Alpha in September last year, giving the Philadelphia-based biotech's stock a "buy" rating. In that note, I provided an overview of the company's progress since its IPO in 2019, which raised ~$75m at $11 per share. The (relatively) unique aspect of Cabaletta's business is  ...